Journal of diabetes and treatment最新文献_第3页

Assessment and Comparison of Safety and Efficacy between Topical Capsaicin (0.025%), Capsaicin (0.075%), and Oral Pregabalin in the Treatment of Diabetic Peripheral Neuropathy 外用0.025%辣椒素、0.075%辣椒素和口服普瑞巴林治疗糖尿病周围神经病变的安全性和有效性评价与比较

Journal of diabetes and treatment Pub Date : 2022-09-23 DOI: 10.29011/2574-7568.010108

引用次数: 0

Prevalence of the Coeliac Disease among Patients with Type 1 Diabetes Followed Up at the Endocrine Unit in the Lady Ridgeway Hospital for Children Colombo 科伦坡Lady Ridgeway儿童医院内分泌科1型糖尿病患者乳糜泻患病率的随访研究

Journal of diabetes and treatment Pub Date : 2022-08-12 DOI: 10.29011/2574-7568.010106

引用次数: 0

Diabetic Foot Amputation: A Case Report 糖尿病足截肢1例

Journal of diabetes and treatment Pub Date : 2022-08-12 DOI: 10.29011/2574-7568.010105

引用次数: 0

Bioequivalence Study of Fixed-Dose Combination of Remogliflozin Etabonate 100 mg/Vildagliptin 50 mg with Individual Components in Healthy Indian Male Subjects under Fed Conditions 进食条件下印度健康男性100mg / 50mg瑞格列净与单组分固定剂量联合应用的生物等效性研究

Journal of diabetes and treatment Pub Date : 2022-07-18 DOI: 10.29011/2574-7568.010100

Shashank R. Joshi, Jayshree Swain, R. Kodgule, S. Katare, S. Suryawanshi, Kiran, Khaladkar

{"title":"Bioequivalence Study of Fixed-Dose Combination of Remogliflozin Etabonate 100 mg/Vildagliptin 50 mg with Individual Components in Healthy Indian Male Subjects under Fed Conditions","authors":"Shashank R. Joshi, Jayshree Swain, R. Kodgule, S. Katare, S. Suryawanshi, Kiran, Khaladkar","doi":"10.29011/2574-7568.010100","DOIUrl":"https://doi.org/10.29011/2574-7568.010100","url":null,"abstract":"Bioequivalence study of Fixed-Dose Combination of Remogliflozin Etabonate 100 mg/Vildagliptin 50 mg with Individual Components in Healthy Indian Male Subjects Under Fed Conditions. Abstract Background and Objective. Combination of sodium glucose co-transporter-2 (SGLT2) and dipeptidyl peptidase-4 (DPP4) inhibitors has shown promising results in the treatment of type 2 diabetes mellitus. A Fixed Dose Combination (FDC) of remogliflozin and vildagliptin will reduce the pill burden and help improve treatment compliance. This study was conducted to establish the bioequivalence of an oral FDC of remogliflozin etabonate (100mg) and vildagliptin (50mg) with single tablets of Remo ® (remogliflozin etabonate; 100 mg) and Galvus ® (vildagliptin; 50 mg) Methods. Pharmacokinetic parameters i.e. maximum concentration (C max ) and area under concentration–time curve (AUC 0-t , and AUC 0-∞ ) were calculated to determine bioequivalence. Safety was assessed and adverse events were monitored throughout the trial. Results. For both remogliflozin and vildagliptin, 90% confidence interval (CI) of the geometric least-squares mean ratios of C max , AUC 0-t , and AUC 0-∞ values between FDC and reference products fell within the standard regulatory bioequivalence range of 85.0-125.0%. Remogliflozin etabonate and its metabolite, GSK279782, also demonstrated geometric least-squares mean ratio of ~ 100%. No clinical abnormalities or adverse events were reported during the study.","PeriodicalId":73707,"journal":{"name":"Journal of diabetes and treatment","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41354376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Efficacy and Safety of Fixed-dose Combination of Teneligliptin and Pioglitazone versus Respective Monotherapies in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: A Phase III Randomized Parallel Group Study Teneliglitin和Pioglitazone固定剂量联合治疗二甲双胍控制不足的2型糖尿病患者的疗效和安全性：一项III期随机平行组研究

Journal of diabetes and treatment Pub Date : 2022-07-16 DOI: 10.29011/2574-7568.010102

引用次数: 0

A Randomized, Open-Label, Crossover Trial to Assess Bioequivalence of Teneligliptin 10 mg Twice-Daily with Teneligliptin 20 mg Once-Daily 一项随机、开放标签、交叉试验评估Teneligliptin 10mg每日两次与Teneligliptin 20mg每日一次的生物等效性

Journal of diabetes and treatment Pub Date : 2022-07-05 DOI: 10.29011/2574-7568.010101

引用次数: 0

A Prospective Multicenter Open-label Study to Assess Effect of Remogliflozin on Glycemic Variability Compared to Dapagliflozin Using Continuous Glucose Monitoring (REMIT - GV study) 一项评估瑞格列净与达格列净在持续血糖监测下对血糖变异性影响的前瞻性多中心开放标签研究(REMIT - GV研究)

Journal of diabetes and treatment Pub Date : 2022-06-10 DOI: 10.29011/2574-7568.001099

Bipin Sethi, K. D. Modi, K. Srikanth, S. Erande, K. Khaladkar, Manoj Kumar, Sumit Bhushan, S. Suryawanshi, H. Barkate

引用次数: 0

Psychological Aspects in the Use of Telemedicine in Diabetes Mellitus 远程医疗在糖尿病患者中的应用

Journal of diabetes and treatment Pub Date : 2022-03-31 DOI: 10.29011/2574-7568.001098

引用次数: 0

Prevalence of Antidiabetic Drugs Prescription in Type 2 Diabetes and Chronic Kidney Disease Patients from Tâmega e Sousa Tâmega e Sousa地区2型糖尿病和慢性肾脏病患者抗糖尿病药物处方的患病率

Journal of diabetes and treatment Pub Date : 2022-03-28 DOI: 10.29011/2574-7568.001097

Sousa, R. Abreu

{"title":"Prevalence of Antidiabetic Drugs Prescription in Type 2 Diabetes and Chronic Kidney Disease Patients from Tâmega e Sousa","authors":"Sousa, R. Abreu","doi":"10.29011/2574-7568.001097","DOIUrl":"https://doi.org/10.29011/2574-7568.001097","url":null,"abstract":"Background: Diabetes mellitus is the most prevalent cause of Chronic Kidney Disease (CKD). Recently, guidelines have supported the use of SGLT-2 inhibitors as first-line therapy in type 2 diabetes mellitus. There is a lack of epidemiologic studies on the patterns and trends of antidiabetic drugs prescription most commonly used in clinical practice in CKD patients. Methods: A descriptive and observational single-center study was performed in 2020, by analyzing patients followed up in the Nephrology Department of the Centro Hospitalar Tâmega e Sousa, Portugal. Results: A total of 566 patients were observed over one year and 47.0% had diabetes mellitus (n=266). Mean age of diabetic patients was of 74±10.8 years, with a male gender predominance of 57.1% (n=152). Diabetic nephropathy was present in 89.5% (n=238). Remaining causes of chronic kidney disease (CKD) were hypertensive nephrosclerosis (n=12), chronic pyelonephritis (n=6), IgA nephropathy (n=2), focal segmental glomerulosclerosis (n=2), acute tubular necrosis (n=2), mesangio proliferative glomerulonephritis (n=1), immunotactoid glomerulonephritis (n=1), minimal change disease (n=1) and uncertainly (n=1). Mean HbA1c was 7.2±1.4. Mean value of plasmatic creatinine was 1.8±0.7 mg/dL (ClCr: 47±29.6 mL/min) and proteinuria was 1339±2794 mg/24h. One-third of patients were in CKD stage 3b (33.4%), 30.4% in stage 4 and 2.6% in stage 5. Oral antidiabetic drugs were prescribed an average of 1.5±0.7. DPP-4 inhibitors were the most commonly prescribed class of antidiabetic drugs (56.4%), followed by biguanides (32.7%) and SGLT-2 inhibitors (22.6%; n=60). Conclusions: A new pattern in antidiabetic drugs prescription could be seen but there is an even broader edge for treatment optimization in type 2 Diabetes Mellitus. Journal of Diabetes and Treatment Abreu R. J Diabetes Treat 7: 1097. www.doi.org/10.29011/2574-7568.001097 www.gavinpublishers.com","PeriodicalId":73707,"journal":{"name":"Journal of diabetes and treatment","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44066686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of Cilostazol as an Antiplatelet Agent on Diabetic Nephropathy with Macroalbuminuria: A Randomized, Double-Blind, Placebo-Controlled Trial (ATP-DN) 西洛他唑抗血小板药物对糖尿病肾病伴大量白蛋白尿的影响:一项随机、双盲、安慰剂对照试验(ATP-DN)

Journal of diabetes and treatment Pub Date : 2022-01-13 DOI: 10.29011/2574-7568.001095

N. Seki, Hideo Nishimura, S. Ohtani, M. Nishimura, M. Ujihara, Yuji Aoki, M. Shida, Tsuyoshi Tanaka, Kensei, Yahata, H. Taki, Kiniko Kawada, K. Hida, Yoshiaki, Oda, T. Sumii, H. Yoshizumi, Y. Kawabe, H. Kikuchi, Y. Hoshiyama

{"title":"Effect of Cilostazol as an Antiplatelet Agent on Diabetic Nephropathy with Macroalbuminuria: A Randomized, Double-Blind, Placebo-Controlled Trial (ATP-DN)","authors":"N. Seki, Hideo Nishimura, S. Ohtani, M. Nishimura, M. Ujihara, Yuji Aoki, M. Shida, Tsuyoshi Tanaka, Kensei, Yahata, H. Taki, Kiniko Kawada, K. Hida, Yoshiaki, Oda, T. Sumii, H. Yoshizumi, Y. Kawabe, H. Kikuchi, Y. Hoshiyama","doi":"10.29011/2574-7568.001095","DOIUrl":"https://doi.org/10.29011/2574-7568.001095","url":null,"abstract":"ISSN: 2574-7568 1 Volume 7; Issue 01 Research Article Effect of Cilostazol as an Antiplatelet Agent on Diabetic Nephropathy with Macroalbuminuria: A Randomized, Double-Blind, Placebo-Controlled Trial (ATP-DN) Naoto Seki1*, Hideo Nishimura2, Sumire Ohtani3, Motonobu Nishimura1, Makoto Ujihara4, Yuji Aoki5, Mikio Shida6, Tsuyoshi Tanaka7, Kensei Yahata8, Hideki Taki9, Kiniko Kawada10, Kazuyuki Hida11, Yoshiaki Oda12, Toshihiko Sumii13, Hideyuki Yoshizumi14, Yojiro Kawabe15, Hidetoshi Kikuchi16, Yoshiharu Hoshiyama17 1National Hospital Organization, Chiba-East National Hospital, Chiba, Japan 2National Hospital Organization, Asahikawa Medical Center, Asahikawa, Japan 3National Hospital Organization, Saitama National Hospital, Wako, Japan 4National Hospital Organization, Yokohama Medical Center, Yokohama, Japan 5National Hospital Organization, Matsumoto Medical Center, Matsumoto Hospital, Matsumoto Japan 6National Hospital Organization, Shizuoka Medical Center, Shizuoka, Japan 7National Hospital Organization, Mie Chuo Medical Center, Mie, Japan 8National Hospital Organization, Kyoto Medical Center, Kyoto, Japan 9National Hospital Organization, Osaka Medical Center, Osaka, Japan 10National Hospital Organization, Hamada Medical Center, Hamada, Japan 11National Hospital Organization, Okayama Medical Center, Okayama, Japan 12National Hospital Organization, Higashihiroshima Medical Center, Higashihiroshima, Japan 13National Hospital Organization, Kokura Medical Center, Kitakyusyu, Japan 14National Hospital Organization, Kusyu Medical Center, Fukuoka, Japan 15National Hospital Organization, Ureshino Medical Center, Ureshino, Japan 16National Hospital Organization, Beppu Medical Center, Beppu, Japan 17School of Nursing, Yokohama Soei University, Kanagawa, Japan","PeriodicalId":73707,"journal":{"name":"Journal of diabetes and treatment","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47713409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0